

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

STEVEN L. HIGHLANDER
PARTNER

INTERNET ADDRESS:
SHIGLDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

GAU 1615
#26 C
Office
1/28/03
HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

RECEIVED
JAN 23 2003
F&J CENTER 1600/2900

January 14, 2003

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

January 14, 2003
Date

Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

RE: SN 09/460,292 "COMPOSITIONS AND METHODS OF MODULATING CHOLESTEROL METABOLISM" – David L. Mangelsdorf et al.
F&J Matter Ref.: UTSD:596 / 10017652

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) Amendment and Request for Reconsideration Under 37 C.F.R. §1.111; and
- (2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

No other fees are believed due; however, should any other fees be due, applicants authorizes the Commissioner to debit Fulbright & Jaworski Deposit Acct. No. 55-1212/UTSD:596.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642

SLH/fb

Encl.: As noted.

25251693.1